TY - JOUR T1 - Disease control in patients with ankylosing spondylitis in real clinical practice in Spain: Results of the MIDAS study JO - Reumatología Clínica (English Edition) T2 - AU - de Miguel,Eugenio AU - Fernández-Carballido,Cristina AU - Gratacós,Jordi AU - Pablos,José L. AU - Juanola,Xavier AU - Ariza,Rafael AU - Terradas-Montana,Pau AU - Sanabra,Cristina AU - Sastré,Carlos SN - 21735743 M3 - 10.1016/j.reumae.2022.01.004 DO - 10.1016/j.reumae.2022.01.004 UR - https://reumatologiaclinica.org/en-disease-control-in-patients-with-articulo-S2173574323000084 AB - Introduction and objectivesUnderstanding the disease activity is fundamental to improve patient prognosis and patients’ quality of life. MiDAS study described disease activity in ankylosing spondylitis (AS) Spanish patients and the proportion of them with controlled disease. MethodsObservational, cross-sectional, multicenter study carried out under conditions of routine clinical practice. Adult (≥18 years) patients with ≥6 months since AS diagnosis treated ≥3 months prior to inclusion. The primary endpoint was the percentage of patients with low disease activity assessed through BASDAI (primary endpoint) and ASDAS-CRP (secondary endpoint). Results313 AS patients included: 75.7% male; 78.5% HLA-B*27 positive; mean (SD) baseline age of 50.4 (12.0) years; mean (SD) disease duration of 15.5 (11.6) years; 73.5% were treated with biological disease-modifying antirheumatic drugs (DMARDs), 22.4% with non-biological DMARDs and 53.7% with non-steroidal anti-inflammatory drugs, alone or in combination. Monotherapy with biologics and non-biologics was used by 29.7% and 26.8% of patients, respectively. According to BASDAI, 38.0% were in remission (BASDAI≤2) and 64.5% showed adequate disease control (BASDAI<4). According to ASDAS-CRP, 29.4% achieved remission (ASDAS-CRP<1.3) and 28.1% low disease activity (1.3≤ASDAS-CRP<2.1). ConclusionsAlmost two thirds of the AS patients recruited had low disease activity, with about one third of them being in remission (BASDAI≤2, ASDAS-CRP<1.3). These results highlight the existing room for improvement in treating AS patients in clinical practice. ER -